Tianjin Zhong Xin Pharmaceutical Group says Jinhushen Biological Medical Science and Technology has completed its acquisition in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH) on March 26.

Jinhushen, on Dec 19, 2020, entered into a sale and purchase agreement (SPA) with Tianjin Bohai State-owned Assets to acquire a 67% stake in TPH.

Further to the completion of the acquisition, Tianjin Pharmaceutical will be making the S shares chain offer according to rule 14.1 of the code.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook